{"id":32746,"date":"2024-07-03T12:28:55","date_gmt":"2024-07-03T12:28:55","guid":{"rendered":"https:\/\/ibima.eu\/estudio-en-fase-iib-aleatorizado-con-doble-enmascaramiento-comparativo-con-placebo-y-multicentrico-para-evaluar-la-eficacia-y-la-seguridad-de-prasinezumab-intravenoso-en-participantes-con-enfermed\/"},"modified":"2024-07-03T12:28:55","modified_gmt":"2024-07-03T12:28:55","slug":"estudio-en-fase-iib-aleatorizado-con-doble-enmascaramiento-comparativo-con-placebo-y-multicentrico-para-evaluar-la-eficacia-y-la-seguridad-de-prasinezumab-intravenoso-en-participantes-con-enfermed","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-en-fase-iib-aleatorizado-con-doble-enmascaramiento-comparativo-con-placebo-y-multicentrico-para-evaluar-la-eficacia-y-la-seguridad-de-prasinezumab-intravenoso-en-participantes-con-enfermed\/","title":{"rendered":"Estudio en fase IIb, aleatorizado, con doble enmascaramiento, comparativo con placebo y multic\u00e9ntrico, para evaluar la eficacia y la seguridad de prasinezumab intravenoso en participantes con enfermedad de parkinson incipiente"},"content":{"rendered":"
LUCIA GARCIA TRUJILLO – ENSAYO CLINICO COMERCIAL – F. HOFFMANN-LA ROCHE LTD<\/p>","protected":false},"excerpt":{"rendered":"
LUCIA GARCIA TRUJILLO – ENSAYO CLINICO COMERCIAL – F. HOFFMANN-LA ROCHE LTD<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2283],"tags":[],"class_list":["post-32746","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-c-01-ensayos-clinicos"],"acf":[],"yoast_head":"\n